• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neuropace Inc (NQ: NPCE )

    8.260 +0.190 (+2.35%)
    Streaming Delayed Price Updated: 11:09 AM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,560
    Open 8.110
    Bid (Size) 8.160 (4)
    Ask (Size) 8.300 (1)
    Prev. Close 8.070
    Today's Range 8.070 - 8.340
    52wk Range 3.910 - 18.15
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024
    NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -15.54%
    -15.54%
    1 Month
    +23.47%
    +23.47%
    3 Month
    -39.09%
    -39.09%
    6 Month
    -43.77%
    -43.77%
    1 Year
    +106.50%
    +106.50%

    More News

    Read More
    NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
    From NeuroPace, Inc.
    Via GlobeNewswire
    The Latest Analyst Ratings For NeuroPace
    Via Benzinga
    NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Recap: NeuroPace Q4 Earnings
    Via Benzinga
    Earnings Preview: NeuroPace
    Via Benzinga
    A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts
    Via Benzinga
    NeuroPace Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
    Via Benzinga
    NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
    From NeuroPace, Inc.
    Via GlobeNewswire
    Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
    Via InvestorPlace
    Earnings Scheduled For March 5, 2024
    Via Benzinga
    Breaking Down NeuroPace: 6 Analysts Share Their Views
    Via Benzinga
    NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From NeuroPace, Inc.
    Via GlobeNewswire
    NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
    From NeuroPace, Inc.
    Via GlobeNewswire
    Expert Ratings for NeuroPace
    Via Benzinga
    NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
    From NeuroPace, Inc.
    Via GlobeNewswire
    Expert Ratings for NeuroPace
    Via Benzinga
    Earnings Scheduled For November 6, 2023
    Via Benzinga
    NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
    From NeuroPace, Inc.
    Via GlobeNewswire
    Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
    From NeuroPace, Inc.
    Via GlobeNewswire
    NeuroPace Announces RNS System Enhancements Designed to Streamline Care
    From NeuroPace, Inc.
    Via GlobeNewswire
    NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
    From NeuroPace, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.